2025
Safety of Stimulants Across Patient Populations
Oliva H, Prudente T, Mayerson T, Mignosa M, Oliva I, Potenza M, Jegede O, Angarita G. Safety of Stimulants Across Patient Populations. JAMA Network Open 2025, 8: e259492. PMID: 40343695, PMCID: PMC12065045, DOI: 10.1001/jamanetworkopen.2025.9492.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderRandomized clinical trialsAdverse eventsStimulant medicationData extractionSafety of stimulationRisk ratioIncreased riskMethodological quality assessmentPreferred Reporting ItemsPatient populationClinical conditionsDiverse patient populationsRisk of biasSafety of stimulant medicationsUnclear risk of biasTreatment of attention-deficit/hyperactivity disorderOverall AEsRandom-effects modelWeb of ScienceBinge eating disorderStimulant use disorderComprehensive literature searchMain OutcomesReporting Items
2024
Association of multiple sclerosis with psychiatric disorders and homelessness among veterans in the United States Department of Veterans Affairs healthcare system
Silveira S, Beydoun H, Tsai J. Association of multiple sclerosis with psychiatric disorders and homelessness among veterans in the United States Department of Veterans Affairs healthcare system. CNS Spectrums 2024, 29: 433-440. PMID: 39576134, DOI: 10.1017/s1092852924002165.Peer-Reviewed Original ResearchSubstance use disordersPsychiatric disordersUse disorderMental illnessDiagnosis of cannabis use disorderAssociated with diagnosisDiagnosis of alcohol use disorderCannabis use disorderPosttraumatic stress disorderStimulant use disorderAlcohol use disorderHealthcare systemService-connected disability ratingDepartment of Veterans Affairs healthcare systemSample of veteransPrevalence of mental illnessCharlson Comorbidity IndexGroup of veteransManagement of mental illnessVeterans Affairs Healthcare SystemVA healthcare systemMS diagnosisSchizophrenia/schizoaffective disorderCorporate Data WarehouseDepressive disorderDisorders due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders due to Substance Use: Stimulants. 2024, 2843-2932. DOI: 10.1007/978-3-030-51366-5_26.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequencesTreatment for Co-Occurring Stimulant and Opioid Use Disorders
Howell B, Lin L, Coughlin L. Treatment for Co-Occurring Stimulant and Opioid Use Disorders. JAMA Psychiatry 2024, 81: 853-854. PMID: 38985457, DOI: 10.1001/jamapsychiatry.2024.1775.Peer-Reviewed Original Research
2023
Cannabis use disorder, suicide attempts, and self-harm among adolescents: A national inpatient study across the United States
Oladunjoye A, Li E, Aneni K, Onigu-Otite E. Cannabis use disorder, suicide attempts, and self-harm among adolescents: A national inpatient study across the United States. PLOS ONE 2023, 18: e0292922. PMID: 37847698, PMCID: PMC10581466, DOI: 10.1371/journal.pone.0292922.Peer-Reviewed Original ResearchConceptsUse disordersSuicide attemptsPotential confoundersTenth Revision diagnostic codesSuicide riskCross-sectional observation studyDiagnosis of CUDNational Inpatient StudyNationwide Inpatient SamplePresence of depressionNicotine use disorderRevision diagnostic codesSubstance use disordersStimulant use disorderAlcohol use disorderCocaine use disorderPrimary outcomeInpatient studyHigh-risk adolescentsInpatient SampleDiagnostic codesInpatient settingHigh riskInternational ClassificationAdolescent hospitalizationExpert consensus‐based guidance on approaches to opioid management in individuals with advanced cancer‐related pain and nonmedical stimulant use
Jones K, Khodyakov D, Han B, Arnold R, Dao E, Morrison J, Kapo J, Meier D, Paice J, Liebschutz J, Ritchie C, Merlin J, Bulls H. Expert consensus‐based guidance on approaches to opioid management in individuals with advanced cancer‐related pain and nonmedical stimulant use. Cancer 2023, 129: 3978-3986. PMID: 37691479, PMCID: PMC10910244, DOI: 10.1002/cncr.34921.Peer-Reviewed Original ResearchConceptsCancer-related painConsensus-based guidanceStimulant useUncertain appropriatenessOpioid taperingLonger prognosisShort prognosisPalliative careAddiction expertsNonmedical stimulant useRAND/UCLAStimulant use disorderHarm reduction measuresAdvanced cancerPatient prognosisClinical appropriatenessPainUse disordersPrognosisPatientsExpert consensusOpioidsCancerDelphi panelCliniciansValidation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians
Di Paola A, Farabee D, Springer S. Validation of Two Diagnostic Assessments for Opioid and Stimulant Use Disorder for Use by Non‐Clinicians. Psychiatric Research And Clinical Practice 2023, 5: 78-83. PMID: 37711754, PMCID: PMC10499189, DOI: 10.1176/appi.prcp.20230022.Peer-Reviewed Original ResearchStimulant use disorderUse disordersSevere opioid use disorderMini International Neuropsychiatric InterviewDiagnostic assessmentOpioid use disorderDisorder assessmentInternational Neuropsychiatric InterviewDSM-IV criteriaHarm reduction interventionsNon-clinical staffTraditional diagnostic assessmentInternal consistencyDSM-5 versionValid measureOpioid dependenceOpioid misuseImmediate treatmentNeuropsychiatric InterviewOpioid epidemicDisorder modulesOverdose deathsReduction interventionsNon cliniciansRapid diagnosisDisorders Due to Substance Use: Stimulants
Sevarino K, Farrell M. Disorders Due to Substance Use: Stimulants. 2023, 1-90. DOI: 10.1007/978-3-030-42825-9_26-1.Peer-Reviewed Original ResearchBody of preclinical researchAssociated with significant impairmentStimulant use disorderFDA-approved medicationsBehavioral therapyOccupational functioningUse disorderPrescribed stimulantsSignificant impairmentHepatitis CClinical featuresSubstance usePharmacological therapyMedical illnessPreclinical researchRates of overdose deathsCardiovascular diseaseDisordersElevated ratesElevated riskTherapyPotential targetOverdose deathsStimulationAdverse consequencesTesting and Case Rates of Gonorrhea, Chlamydia, Syphilis, and HIV among People with Substance Use Disorders in the Veterans Health Administration
Villamagna A, Beste L, Borgerding J, Lowy E, Hauser R, Ross D, Maier M. Testing and Case Rates of Gonorrhea, Chlamydia, Syphilis, and HIV among People with Substance Use Disorders in the Veterans Health Administration. Journal Of Addiction Medicine 2023, 17: 387-393. PMID: 37579093, DOI: 10.1097/adm.0000000000001134.Peer-Reviewed Original ResearchConceptsSubstance use disordersVeterans Health AdministrationMental health diagnosesUse disordersTesting ratesCase ratesTest positivityHealth AdministrationSUD groupSingle substance use disorderVeterans Health Administration patientsMultiple substance use disordersStimulant useHealth diagnosisHIV test positivityInfections (STI) testing ratesNational retrospective analysisHigh STI ratesLow testing ratesStimulant use disorderAlcohol use disorderInfection testingNational cohortSTI ratesRetrospective analysis
2022
Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood
Cabrera‐Mendoza B, Stertz L, Najera K, Selvaraj S, Teixeira A, Meyer T, Fries G, Walss‐Bass C. Within subject cross‐tissue analyzes of epigenetic clocks in substance use disorder postmortem brain and blood. American Journal Of Medical Genetics Part B Neuropsychiatric Genetics 2022, 192: 13-27. PMID: 36056652, PMCID: PMC9742183, DOI: 10.1002/ajmg.b.32920.Peer-Reviewed Original ResearchConceptsSubstance use disordersStimulant use disorderUse disordersPostmortem brainsAlcohol use disorderBrains of individualsBlood tissueBiological agingSubgroup analysisBrain valuesEpigenetic clocksSUD groupPeripheral measuresAging StudyDisordersBrainPatientsBloodDNA methylation changesSame individualTissueIndividualsMethylation changesOpioidsTissue specificity
2021
168. Testing, Diagnosis, and Incidence of Sexually Transmitted Infections Among People with Substance Use Disorders in the Veterans Health Administration, 2019
Villamagna H, Beste L, Borgerding J, Lowy E, Hauser R, Maier M. 168. Testing, Diagnosis, and Incidence of Sexually Transmitted Infections Among People with Substance Use Disorders in the Veterans Health Administration, 2019. Open Forum Infectious Diseases 2021, 8: 101-101. PMCID: PMC8644516, DOI: 10.1093/ofid/ofab466.168.Peer-Reviewed Original ResearchSubstance use disordersAlcohol use disorderSingle substance use disorderStimulant use disorderVeterans Health AdministrationUse disordersSTI testingElectronic medical recordsIncidence rateHigh incidenceTest positivityVHA electronic medical recordsMultiple substance use disordersComprehensive STI testingRetrospective cohort studyOpioid use disorderMental health diagnosesIncidence of syphilisRegional Medical CenterCorporate Data WarehouseDepartment of HealthRate of testingCohort studyVHA careMedical records
2020
Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder
Worhunsky PD, Angarita GA, Zhai ZW, Matuskey D, Gallezot JD, Malison RT, Carson RE, Potenza MN. Multimodal investigation of dopamine D2/D3 receptors, default mode network suppression, and cognitive control in cocaine-use disorder. Neuropsychopharmacology 2020, 46: 316-324. PMID: 33007778, PMCID: PMC7852666, DOI: 10.1038/s41386-020-00874-7.Peer-Reviewed Original ResearchConceptsCocaine use disorderDMN suppressionDefault mode networkCognitive controlExecutive functioningStroop performanceCognitive control processesHealthy comparison participantsModerated-mediation analysisImproved task performanceStroop taskStimulant use disorderCognitive performanceTask performanceComparison participantsAddicted populationMode networkNetwork suppressionFMRI dataCUD participantsHC individualsMultimodal investigationControl processIndirect effectsD2R levels
2019
The prevalence of substance use disorders among community-based adults with legal problems in the U.S
Moore KE, Oberleitner L, Pittman BP, Roberts W, Verplaetse TL, Hacker RL, Peltier MR, McKee SA. The prevalence of substance use disorders among community-based adults with legal problems in the U.S. Addiction Research & Theory 2019, 28: 165-172. PMID: 32952490, PMCID: PMC7500665, DOI: 10.1080/16066359.2019.1613524.Peer-Reviewed Original ResearchDrug use disordersSubstance use disordersAlcohol use disorderUse disordersAlcohol-related legal problemsSUD diagnosisSystem involvementAUD diagnosisCurrent AUD diagnosisCurrent alcohol use disorderLifetime alcohol use disorderNational prevalence estimatesStimulant use disorderCommunity-based adultsJustice system involvementLifetime AUD diagnosisDUD diagnosesPrevalence estimatesDiagnosisDisordersAdultsDSM-5Continued needIntervention effortsRepresentative U.S. sampleUtilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders
Tsai J, Gu X. Utilization of addiction treatment among U.S. adults with history of incarceration and substance use disorders. Addiction Science & Clinical Practice 2019, 14: 9. PMID: 30836991, PMCID: PMC6402155, DOI: 10.1186/s13722-019-0138-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersUse disorder treatmentAlcohol use disorder treatmentDrug use disorder treatmentSUD treatmentUse disordersHistory of incarcerationDisorder treatmentU.S. adultsIncarceration historySUD treatment useLifetime substance use disorderHeroin use disorderOpioid use disorderPopulation-based sampleStimulant use disorderNational Epidemiologic SurveyPopulation of adultsPublic health approachRelated Conditions-IIICocaine use disorderHigh prevalenceTreatment useEpidemiologic SurveyLifetime history
2018
Stimulants and Mood Disorders
MacLean R, Sofuoglu M. Stimulants and Mood Disorders. Current Addiction Reports 2018, 5: 323-329. DOI: 10.1007/s40429-018-0212-0.Peer-Reviewed Original ResearchStimulant use disorderMood disordersUse disordersSUD comorbidityClinical trialsComorbid substance use disorderRecent FindingsEpidemiological studiesCo-occurring mood disordersSubstance use disordersMethamphetamine use disorderMajority of trialsClinical outcomesPharmacological treatmentTreatment responseNeurobiological mechanismsDisordersMultiple studiesTrialsComorbiditiesPatientsDiagnosisMoodTreatmentPurposeToEpidemiology
2016
Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders
Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive Function as a Transdiagnostic Treatment Target in Stimulant Use Disorders. Journal Of Dual Diagnosis 2016, 12: 90-106. PMID: 26828702, PMCID: PMC4837011, DOI: 10.1080/15504263.2016.1146383.Peer-Reviewed Original ResearchConceptsStimulant use disorderTransdiagnostic treatment targetExecutive controlAutomatic processCognitive impairmentUse disordersAddictive behaviorsCognitive functionDual-process modelCognitive behavioral therapyMaintenance of addictionCertain cognitive impairmentsPoor treatment retentionTreatment targetsAttentional biasApproach biasCognitive rehabilitationResponse inhibitionCognitive enhancementSustained attentionBehavioral therapyBehavioral treatmentAnxiety disordersBehavioral approachRates of lifetime
2015
Measures of outcome for stimulant trials: ACTTION recommendations and research agenda
Kiluk BD, Carroll KM, Duhig A, Falk DE, Kampman K, Lai S, Litten RZ, McCann DJ, Montoya ID, Preston KL, Skolnick P, Weisner C, Woody G, Chandler R, Detke MJ, Dunn K, Dworkin RH, Fertig J, Gewandter J, Moeller FG, Ramey T, Ryan M, Silverman K, Strain EC. Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug And Alcohol Dependence 2015, 158: 1-7. PMID: 26652899, PMCID: PMC4698050, DOI: 10.1016/j.drugalcdep.2015.11.004.Peer-Reviewed Original ResearchConceptsStimulant use disorderClinical trialsMeaningful outcome measuresUse disordersTreatment successOutcome measuresStimulant abstinenceAddiction Clinical Trial TranslationsFuture clinical trialsClinical trial endpointsClinical trial dataAlcohol use disorderMeasures of outcomeValidation of PatientStimulant trialsTrial endpointsEfficacious pharmacotherapiesUrine testingSustained abstinenceTrial dataSecondary analysisStimulant useTrialsPsychosocial benefitsDisordersStimulant Use Disorders
Sevarino K, Shelby B. Stimulant Use Disorders. 2015, 1561-1614. DOI: 10.1002/9781118753378.ch80.Peer-Reviewed Original ResearchStimulant use disorderUse disordersMonths of treatmentOngoing psychosocial stressorsSubstance abuse treatmentCocaine use disorderDisease courseAcute cravingAppropriate treatmentHigh riskPsychosocial stressorsAbuse treatmentNonmedical useCrystal methamphetamineDrug abuseDisordersMethamphetamineTreatmentPrescription stimulantsAmphetamineStimulantsPatientsRelapseDextroamphetamineMethylphenidate
2014
Substance use in older HIV-infected patients
Edelman EJ, Tetrault JM, Fiellin DA. Substance use in older HIV-infected patients. Current Opinion In HIV And AIDS 2014, 9: 317-324. PMID: 24824888, PMCID: PMC4175926, DOI: 10.1097/coh.0000000000000069.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersSubstance useTreatment optionsHealth consequencesPotential treatment optionStimulant use disorderRelated health consequencesOlder HIVAntiretroviral therapyHIVPatientsBrief counselingHealth outcomesEffective interventionsComplex needsMedicationsDisordersCounseling strategiesInterventionOutcomesTobaccoLife courseOptionsTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply